Pliant Therapeutics Announces Promising Results from Phase 1 Trial of PLN-101095
Pliant Therapeutics, a biotechnology company based in South San Francisco, recently announced preliminary data from the first three cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095. This investigational drug, which is an integrin αvβ8 and αvβ1 inhibitor, is being studied in combination with pembrolizumab, an immune checkpoint inhibitor (ICI), in patients with advanced or metastatic solid tumors that have progressed despite prior ICI therapy.
Antitumor Activity Observed
According to the company’s press release, partial responses were observed in 50% of patients at the highest dose tested to date. These responses were reported across multiple tumor types, including colorectal, gastric, and ovarian cancers. The duration of response and overall survival data are not yet available.
Well Tolerated Across All Doses
The press release also reported that PLN-101095 was generally well tolerated across all doses. The most common adverse events were gastrointestinal in nature, including diarrhea, nausea, and vomiting. No dose-limiting toxicities were reported.
Impact on Individuals
For individuals with advanced or metastatic solid tumors that have progressed despite prior ICI therapy, these results offer a glimmer of hope. The combination of PLN-101095 and pembrolizumab may provide a new treatment option for those who have exhausted other therapeutic avenues. However, it is important to note that these are early-stage trial results and more data is needed to fully understand the safety and efficacy of this combination.
Impact on the World
If these results hold up in larger, more diverse patient populations and are confirmed in later-stage clinical trials, this combination could have a significant impact on the world of cancer treatment. It could offer a new approach for treating ICI-refractory solid tumors, potentially extending lives and improving quality of life for patients. Additionally, it could provide a new revenue stream for Pliant Therapeutics and other companies working on similar drugs.
Conclusion
Pliant Therapeutics’ announcement of promising results from its Phase 1 trial of PLN-101095 in combination with pembrolizumab offers hope for individuals with advanced or metastatic solid tumors that have progressed despite prior ICI therapy. However, more data is needed to fully understand the safety and efficacy of this combination. If these results hold up in larger, more diverse patient populations and are confirmed in later-stage clinical trials, this could offer a new approach for treating ICI-refractory solid tumors and potentially extend lives and improve quality of life for patients. Additionally, it could provide a new revenue stream for Pliant Therapeutics and other companies working on similar drugs.
- PLN-101095 is an integrin αvβ8 and αvβ1 inhibitor being studied in combination with pembrolizumab in patients with advanced or metastatic solid tumors that have progressed despite prior ICI therapy.
- Partial responses were observed in 50% of patients at the highest dose tested to date, across multiple tumor types.
- PLN-101095 was generally well tolerated across all doses, with the most common adverse events being gastrointestinal in nature.
- If these results hold up in larger, more diverse patient populations and are confirmed in later-stage clinical trials, this combination could offer a new approach for treating ICI-refractory solid tumors and potentially extend lives and improve quality of life for patients.
